Sulphasalazine-induced autoimmune abnormalities in patients with rheumatic disease.
Borg
A A
AA
D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001327:Autoimmune Diseases / Q000139:chemically induced*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use
D018501:Antirheumatic Agents; D012460:Sulfasalazine